Cargando…

Oncofetal reprogramming in tumor development and progression: novel insights into cancer therapy

Emerging evidence indicates that cancer cells can mimic characteristics of embryonic development, promoting their development and progression. Cancer cells share features with embryonic development, characterized by robust proliferation and differentiation regulated by signaling pathways such as Wnt...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Jiangjun, Zhang, Zhe, Zhou, Li, Luo, Maochao, Li, Lei, Li, Bowen, Nice, Edouard C., He, Weifeng, Zheng, Shaojiang, Huang, Canhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10693315/
https://www.ncbi.nlm.nih.gov/pubmed/38045829
http://dx.doi.org/10.1002/mco2.427
_version_ 1785153133388759040
author Cao, Jiangjun
Zhang, Zhe
Zhou, Li
Luo, Maochao
Li, Lei
Li, Bowen
Nice, Edouard C.
He, Weifeng
Zheng, Shaojiang
Huang, Canhua
author_facet Cao, Jiangjun
Zhang, Zhe
Zhou, Li
Luo, Maochao
Li, Lei
Li, Bowen
Nice, Edouard C.
He, Weifeng
Zheng, Shaojiang
Huang, Canhua
author_sort Cao, Jiangjun
collection PubMed
description Emerging evidence indicates that cancer cells can mimic characteristics of embryonic development, promoting their development and progression. Cancer cells share features with embryonic development, characterized by robust proliferation and differentiation regulated by signaling pathways such as Wnt, Notch, hedgehog, and Hippo signaling. In certain phase, these cells also mimic embryonic diapause and fertilized egg implantation to evade treatments or immune elimination and promote metastasis. Additionally, the upregulation of ATP‐binding cassette (ABC) transporters, including multidrug resistance protein 1 (MDR1), multidrug resistance‐associated protein 1 (MRP1), and breast cancer‐resistant protein (BCRP), in drug‐resistant cancer cells, analogous to their role in placental development, may facilitate chemotherapy efflux, further resulting in treatment resistance. In this review, we concentrate on the underlying mechanisms that contribute to tumor development and progression from the perspective of embryonic development, encompassing the dysregulation of developmental signaling pathways, the emergence of dormant cancer cells, immune microenvironment remodeling, and the hyperactivation of ABC transporters. Furthermore, we synthesize and emphasize the connections between cancer hallmarks and embryonic development, offering novel insights for the development of innovative cancer treatment strategies.
format Online
Article
Text
id pubmed-10693315
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-106933152023-12-03 Oncofetal reprogramming in tumor development and progression: novel insights into cancer therapy Cao, Jiangjun Zhang, Zhe Zhou, Li Luo, Maochao Li, Lei Li, Bowen Nice, Edouard C. He, Weifeng Zheng, Shaojiang Huang, Canhua MedComm (2020) Reviews Emerging evidence indicates that cancer cells can mimic characteristics of embryonic development, promoting their development and progression. Cancer cells share features with embryonic development, characterized by robust proliferation and differentiation regulated by signaling pathways such as Wnt, Notch, hedgehog, and Hippo signaling. In certain phase, these cells also mimic embryonic diapause and fertilized egg implantation to evade treatments or immune elimination and promote metastasis. Additionally, the upregulation of ATP‐binding cassette (ABC) transporters, including multidrug resistance protein 1 (MDR1), multidrug resistance‐associated protein 1 (MRP1), and breast cancer‐resistant protein (BCRP), in drug‐resistant cancer cells, analogous to their role in placental development, may facilitate chemotherapy efflux, further resulting in treatment resistance. In this review, we concentrate on the underlying mechanisms that contribute to tumor development and progression from the perspective of embryonic development, encompassing the dysregulation of developmental signaling pathways, the emergence of dormant cancer cells, immune microenvironment remodeling, and the hyperactivation of ABC transporters. Furthermore, we synthesize and emphasize the connections between cancer hallmarks and embryonic development, offering novel insights for the development of innovative cancer treatment strategies. John Wiley and Sons Inc. 2023-12-02 /pmc/articles/PMC10693315/ /pubmed/38045829 http://dx.doi.org/10.1002/mco2.427 Text en © 2023 The Authors. MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Reviews
Cao, Jiangjun
Zhang, Zhe
Zhou, Li
Luo, Maochao
Li, Lei
Li, Bowen
Nice, Edouard C.
He, Weifeng
Zheng, Shaojiang
Huang, Canhua
Oncofetal reprogramming in tumor development and progression: novel insights into cancer therapy
title Oncofetal reprogramming in tumor development and progression: novel insights into cancer therapy
title_full Oncofetal reprogramming in tumor development and progression: novel insights into cancer therapy
title_fullStr Oncofetal reprogramming in tumor development and progression: novel insights into cancer therapy
title_full_unstemmed Oncofetal reprogramming in tumor development and progression: novel insights into cancer therapy
title_short Oncofetal reprogramming in tumor development and progression: novel insights into cancer therapy
title_sort oncofetal reprogramming in tumor development and progression: novel insights into cancer therapy
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10693315/
https://www.ncbi.nlm.nih.gov/pubmed/38045829
http://dx.doi.org/10.1002/mco2.427
work_keys_str_mv AT caojiangjun oncofetalreprogrammingintumordevelopmentandprogressionnovelinsightsintocancertherapy
AT zhangzhe oncofetalreprogrammingintumordevelopmentandprogressionnovelinsightsintocancertherapy
AT zhouli oncofetalreprogrammingintumordevelopmentandprogressionnovelinsightsintocancertherapy
AT luomaochao oncofetalreprogrammingintumordevelopmentandprogressionnovelinsightsintocancertherapy
AT lilei oncofetalreprogrammingintumordevelopmentandprogressionnovelinsightsintocancertherapy
AT libowen oncofetalreprogrammingintumordevelopmentandprogressionnovelinsightsintocancertherapy
AT niceedouardc oncofetalreprogrammingintumordevelopmentandprogressionnovelinsightsintocancertherapy
AT heweifeng oncofetalreprogrammingintumordevelopmentandprogressionnovelinsightsintocancertherapy
AT zhengshaojiang oncofetalreprogrammingintumordevelopmentandprogressionnovelinsightsintocancertherapy
AT huangcanhua oncofetalreprogrammingintumordevelopmentandprogressionnovelinsightsintocancertherapy